Gonadal and erectile dysfunction in diabetics

Hijazi, Rabih; Betancourt-Albrecht, M; Cunningham, Glenn R.

doi:10.1016/j.mcna.2004.04.007

Cited by 10 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…88,89 In patients with type 2 diabetes mellitus, ED is common and is caused mainly by vascular and neurological complications, but low testosterone levels may contribute to ED, libido and body composition changes in these patients. 90 In men with ED attending a sexual dysfunction clinic, 16% had type 2 diabetes mellitus. Of the patients who had both ED and diabetes mellitus, low serum testosterone levels were present in 24.5% compared with 12.6% in those who did not have diabetes even after adjustment for age and BMI.…”

Section: Obesity Metabolic Syndrome Type 2 Diabetes Mellitus and Lomentioning

confidence: 99%

Obesity, low testosterone levels and erectile dysfunction

et al. 2008

View full text Add to dashboard Cite

Obesity is an important risk factor for many common diseases including cardiovascular disease (CVD), type 2 diabetes, cancer and erectile dysfunction (ED). Adipose tissues produce a number of adipokines and cytokines, which affect endothelial and metabolic function resulting in insulin resistance and the metabolic syndrome (risks factors for CVD). Both ED and metabolic syndrome improve with a reduction in body mass index (BMI). The relationships among obesity, metabolic syndrome, ED, sex hormonebinding globulin (SHBG) and serum total and free testosterone levels are complex and often confusing to the physician. It is known that BMI is inversely proportional to serum total testosterone concentrations; low serum SHBG levels in obesity contribute to the low serum total testosterone. Recent studies show that BMI is also inversely proportional to free testosterone concentration. The characteristic low serum testosterone concentrations observed in obese men are also present in men with the metabolic syndrome and type 2 diabetes mellitus. A small proportion of men with ED have hypogonadism; however, the proportion increases if these men are obese with manifestations of the metabolic syndrome or type 2 diabetes mellitus. ED is a common symptom in patients with type 2 diabetes who also have low testosterone levels. This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.

show abstract

Section: Obesity Metabolic Syndrome Type 2 Diabetes Mellitus and Lomentioning

confidence: 99%

Obesity, low testosterone levels and erectile dysfunction

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Diabetes and hypertension are often associated, especially in Type 2 diabetes, and this dramatically increases the risk of ED. A high prevalence of ED in patients with diabetes has been attributed mainly to vascular and neurologic conditions, but also to hypogonadism [49], which has been observed to occur commonly with type 2 diabetes [50], and to result from metabolic syndrome in middle-aged men [51].…”

Section: Chronic Diseasesmentioning

confidence: 99%

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

Aversa¹,

Bruzziches²,

Pili³

et al. 2006

CPD

View full text Add to dashboard Cite

Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothelial function and, erection is a basically vascular event that necessitates an intact endothelium to occur. Hence, ED may be mostly considered as the clinical manifestation of a disease affecting penile circulation as a part of a generalized vascular disorder due to atherosclerosis. Orally active drugs, i.e. phosphodiesterase type-5 inhibitors (PDE5-i), are a group of on-demand drugs licensed for ED treatment and appear to offer advantages over past therapies in terms of ease of administration and cost, and they are now widely advocated as first-line therapy. The recent discovery that chronic not on-demand administration of these drugs may improve erectile and endothelial response in men previously unresponding to on-demand regimes, opens a new scenario in the treatment of men with ED and comorbidities. Finally, the recent approval of PDE5-i sildenafil for the treatment of pulmonary arterial hypertension represents the new challenge for these class of drugs. Aim of this article will be to provide an update on the pathophysiology of ED and how to use of different available PDE5-i in approaching sexual dysfunctional men, pointing out on their characteristic of efficacy and safety and different indications in special sub-populations.

show abstract

“…The patients are usually middle‐aged, and the condition results in a compromised quality of life 1 . MHG is commonly associated with a low serum testosterone and erectile dysfunction that results from degenerative testopathy attributed to insults of hyperglycaemia to the testis 2 . Sexual dysfunction and infertility are frequently accompanied with dysfunction of the Leydig and Sertoli cells in diabetic patients 3,4 .…”

Section: Introductionmentioning

confidence: 99%

Strontium fructose 1,6-diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin-treated rats

Zhang

Liu

Ying

et al. 2009

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

FDP-Sr or testosterone propionate significantly normalized expression and activity of the MMPs-TIMPs system to attenuate changes in serum testosterone, marker enzymes and histology in testis. Effects of FDP-Sr were dose-dependent and comparable with those of testosterone propionate. By supplying extra energy, FDP-Sr could be promising in treating diabetic testopathy by normalizing abnormal MMP-9 and its endogenous inhibitors in testes.

show abstract

Gonadal and erectile dysfunction in diabetics

Cited by 10 publications

References 54 publications

Obesity, low testosterone levels and erectile dysfunction

Obesity, low testosterone levels and erectile dysfunction

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

Strontium fructose 1,6-diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin-treated rats

Contact Info

Product

Resources

About